CellMed AG is a
BTG International group company
History
| 2011 | Acquired by BTG |
|---|---|
| 2010 | Performance of 3 clinical trials (Phase I+II) for CM3 |
| 2008 |
Clinical Phase I/II clinical trial of CellBead® Neuro in Intracerebral Haemorrhage (Stroke, encapsulated MSCs) Option Agreement with AstraZeneca (CM3 - GLP1-Peptide for the treatment of Type 2 diabetes) |
| 2005 | Acquired by Biocompatibles Licence deal with Merz Pharmaceuticals (Novabel, a Dermal Filler) |
| 2004 | Clinical Phase I/II at Charité Berlin (Hypoparathyroidism / encapsulated tissue) |
| 2003 | License and supply agreement with Fresenius AG for an Hb-System (in-vitro diagnostics) |
| 2000 | Founded in December 2000 |
